AP13000 LCMS/MS System

AP13000 LCMS/MS 系统

• 批准号: 6440393
• 负责人: RICHARD TIDWELL
• 金额: $ 43.08万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-05-01 至 2003-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6440393
• 关键词: biomedical equipment purchase; liquid chromatography mass spectrometry

The purpose of this proposal is to provide innovative and dedicated LC/MS/MS technology to the Clinical Pharmacology/ Analytical Chemistry Core (CPACC) of the University of North Carolina at Chapel Hill (UNC-CH) Center for AIDS Research (CFAR) and a group of researchers in the School of Pharmacy. It is estimated that CFAR related studies will utilize approximately 60% of the instrument time. The CPACC provides a centralized unit to facilitate the pharmacology and analytical studies of HIV/AIDS related clinical and basic science research at UNC-CH and collaborating CFAR institutions. Prior to the establishment of the CPACC in 1998, investigators struggled through their analytical and pharmacology needs by relying on the undependable timetables of unfunded colleagues or by contracting out the studies to costly private facilities. The success of the CPACC can be best exemplified by the outstanding score it received from peer reviewers during the CFARs five-year renewal proposal this year (The CFAR is virtually assured of . funding through 2006). This outstanding rating was given despite the fact the reviewers noted " this core is severely limited by a dedicated LC/MS facility". The lack of sufficient facilities at UNC-CH made it necessary for studies requiring LC/MS/MS technology to be carried out night and weekend via an arrangement with GlaxoSmithKline. Unfortunately, because these resources were limited a number of important projects had to be turned down by the CFAR. In addition to the CFAR, a small group of investigators from the School of Pharmacy will utilize 40% of the instrument time. This will serve to assure complete usage of the instrument from the moment of acquisition. Dr. Richard R. Tidwell (Director of the CPACC) will serve as PI of the proposal and will be responsible for all aspects of instrument maintenance and usage. Drs. Hall and Kashuba will prioritize CPA CC use and Dr. Gary Pollack will prioritize use by School of Pharmacy scientists. The instrument will be housed in newly renovated space in the School of Pharmacy.

该提案的目的是为北卡罗来纳大学教堂山分校 (UNC-CH) 艾滋病研究中心 (CFAR) 的临床药理学/分析化学核心 (CPACC) 和药学院的一组研究人员提供创新且专用的 LC/MS/MS 技术。据估计，CFAR 相关研究将占用大约 60% 的仪器时间。 CPACC 提供了一个集中单位，以促进 UNC-CH 和 CFAR 合作机构的 HIV/AIDS 相关临床和基础科学研究的药理学和分析研究。在 1998 年 CPACC 成立之前，研究人员通过依赖没有资金的同事的不可靠时间表或将研究外包给昂贵的私人机构来努力满足他们的分析和药理学需求。 CPACC 的成功最好的例证是它在今年 CFAR 五年更新提案期间从同行评审员处获得的出色分数（CFAR 实际上保证了 2006 年的资金支持）。尽管审稿人指出“该核心受到专用 LC/MS 设施的严重限制”，但仍给予了如此出色的评级。由于 UNC-CH 缺乏足够的设施，需要 LC/MS/MS 技术的研究必须通过葛兰素史克的安排在夜间和周末进行。不幸的是，由于这些资源有限，CFAR 不得不拒绝一些重要的项目。除了 CFAR 之外，药学院的一小群研究人员将利用 40% 的仪器时间。这将有助于确保从购买仪器的那一刻起就可以完全使用该仪器。 Richard R. Tidwell博士（CPACC主任）将担任该提案的PI，负责仪器维护和使用的各个方面。博士。 Hall 和 Kashuba 将优先使用 CPA CC，Gary Pollack 博士将优先由药学院科学家使用。该仪器将安置在药学院新装修的空间内。